Adaptive Biotechnologies Launches National Clinical Trial to Develop Novel T-Cell Based Diagnostic for Lyme Disease

NEXT STORY
Survey of NPs and PAs Reveal How Pharma Can Offer More Support During COVID
PREV STORY
The Asia Pacific E. coli testing market is expected to reach US$ 496.7 million by 2027 from US$ 283.2 million in 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

ContraFect Appoints Lisa Ricciardi as Chief Operating Officer

YONKERS, N.Y., Oct. 05, 2017 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a biotechnology company ...

author_avatar
NASDAQ Market News

NeRRe Therapeutics raises £20 million in a Series B2 financing round

author_avatar
NASDAQ Market News

Agios Presents Positive Results from Phase 2 Study of Mitapivat in Non-transfusion-dependent α- and β-Thalassemia at the European Hematology Association Virtual Congress

author_avatar
NASDAQ Market News